This is the comment from Paul Brennan in the US market entry announcement. If there is latent demand it shouldn`t take too long for meaningful sales.
“Taking direct control of our destiny is a significant step for the growth of PolyNovo. The US is the largest reimbursed dermal matrix market and surgeons have good product awareness and we believe a latent demand of the BTM. Our clinical trial programs have also established good relationships with key opinion leaders, enabling our sales team to identify clear market entry opportunities”.
New article... a world first, page-11
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.30 |
Change
0.000(0.00%) |
Mkt cap ! $1.587B | |||
| Open | High | Low | Value | Volume |
| $2.34 | $2.35 | $2.27 | $1.711M | 744.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 14000 | $2.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.30 | 13896 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PNV (ASX) Chart |